Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25411
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-03-29T12:17:22Z-
dc.date.available2022-03-29T12:17:22Z-
dc.date.issued2011-09-
dc.identifier.citationTuran, A. B. vd. (2011). "Ziprasidone and tardive dystonia: A case report and literature review". Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology, 21(3), 242-245.tr_TR
dc.identifier.issn1017-7833-
dc.identifier.urihttps://doi.org/10.5455/bcp.20110509052149-
dc.identifier.urihttps://www.tandfonline.com/doi/abs/10.5455/bcp.20110509052149-
dc.identifier.urihttp://hdl.handle.net/11452/25411-
dc.description.abstractZiprasidone and tardive dystonia: a case report and literature review A 40-year-old woman with the diagnosis of schizoaffective disorder had been treated with different typical and atypical antipsychotic drugs since the age of 26. Three months after self-discontinuing her medication, she experienced an exacerbation of her psychotic symptoms, so ziprasidone and valproic acid treatment were started. Six months after initiation of the treatment, tardive dystonia was developed involving the neck region. Discontinuation of ziprasidone produced no benefit; thus clozapine, 75 mg/day, was initiated both for psychotic symptoms and dystonia. Due to lack of improvement in the dystonia and because she suffered from side effects, the dosage of clozapine was decreased to 25 mg/day and botulinum toxin type A treatment was administered. She had partial improvement and repeated injections were planned. Although atypical antipsychotic drugs cause fewer extrapyramidal side effects than typical antipsychotics, we must be cautious when prescribing these drugs because of their disabling side effects.en_US
dc.language.isoenen_US
dc.publisherKüre İletişim Grubutr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subjectZiprasidoneen_US
dc.subjectTardive dystoniaen_US
dc.subjectSchizoaffective disorderen_US
dc.subjectCervical dystoniaen_US
dc.subjectBotulinum toxinen_US
dc.subjectValproic aciden_US
dc.subjectAntipsychoticsen_US
dc.subjectClozapineen_US
dc.titleZiprasidone and tardive dystonia: A case report and literature reviewen_US
dc.typeArticleen_US
dc.identifier.wos000296684400011tr_TR
dc.identifier.scopus2-s2.0-80052982368tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.identifier.startpage242tr_TR
dc.identifier.endpage245tr_TR
dc.identifier.volume21tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalKlinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacologytr_TR
dc.contributor.buuauthorTuran, Aslı Bahar-
dc.contributor.buuauthorAkkaya, Cengiz-
dc.contributor.buuauthorEker, Salih Saygın-
dc.contributor.buuauthorSarandöl, Aslı-
dc.contributor.buuauthorKarlı, Necdet-
dc.contributor.researcheridQ-9477-2019tr_TR
dc.indexed.trdizinTrDizintr_TR
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid53664547900tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid6506587942tr_TR
dc.subject.scopusTardive Dyskinesia; Deutetrabenazine; Akathisiaen_US
dc.subject.emtreeBotulinum toxin Aen_US
dc.subject.emtreeChlorpromazineen_US
dc.subject.emtreeClozapineen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeZiprasidoneen_US
dc.subject.emtreeZuclopenthixolen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCase reporten_US
dc.subject.emtreeDisease exacerbationen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeDystoniaen_US
dc.subject.emtreeExtrapyramidal symptomen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHeart rateen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeSalivationen_US
dc.subject.emtreeSchizoaffective psychosisen_US
dc.subject.emtreeSelf medicationen_US
dc.subject.emtreeSide effecten_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTremoren_US
Appears in Collections:Scopus
TrDizin
Web of Science

Files in This Item:
File Description SizeFormat 
Turan_vd_2011.pdf783.78 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons